These data indicate that low nuclear expression of MACROD2 is associated with poor prognosis of patients with stage III MSS primary colon cancer who were treated with 5-FU-based adjuvant chemotherapy. This evidence concerns the gene MACROD2 and malignant colon neoplasm.